GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
The founders of GENEART AG Prof. Dr. Ralf Wagner, Prof. Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management as well as the venture capital companies EquiNet EarlyStage Capital and S-REFIT AG, have signed contracts with Applied Biosystems Deutschland GmbH for selling their GENEART shares.
Applied Biosystems Deutschland GmbH thus holds about 58 % of GENEART AG shares and is planning a voluntary public tender offer for the remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German subsidiary of Life Technologies Corporation, a California/US biotechnology company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees. Furthermore, a cooperation agreement between GENEART AG and Life Technologies has been concluded.
Applied Biosystems Deutschland GmbH thus holds about 58 % of GENEART AG shares and is planning a voluntary public tender offer for the remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German subsidiary of Life Technologies Corporation, a California/US biotechnology company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees. Furthermore, a cooperation agreement between GENEART AG and Life Technologies has been concluded.
